Ratios

		vs industry	vs history
P/B	1.90	HOLX's P/B is ranked higher than 63% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.41 vs. HOLX: 1.90 )	HOLX' s 10-Year P/B Range Min: 0.53   Max: 10.35 Current: 1.9 0.53 10.35
P/S	2.44	HOLX's P/S is ranked lower than 61% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.40 vs. HOLX: 2.44 )	HOLX' s 10-Year P/S Range Min: 0.45   Max: 7.73 Current: 2.44 0.45 7.73
PFCF	23.80	HOLX's PFCF is ranked higher than 65% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 23.35 vs. HOLX: 23.80 )	HOLX' s 10-Year PFCF Range Min: 6.34   Max: 633.75 Current: 23.8 6.34 633.75
EV-to-EBIT	90.9	HOLX's EV-to-EBIT is ranked lower than 65% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 16.12 vs. HOLX: 90.9 )	HOLX' s 10-Year EV-to-EBIT Range Min: 12.7   Max: 181.4 Current: 90.9 12.7 181.4
Shiller P/E	570.2	HOLX's Shiller P/E is ranked lower than 84% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 23.85 vs. HOLX: 570.2 )	HOLX' s 10-Year Shiller P/E Range Min: 96.8   Max: 3556 Current: 570.2 96.8 3556

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	12.1	HOLX's Price/Net Current Asset Value is ranked higher than 64% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 12.40 vs. HOLX: 12.1 )	HOLX' s 10-Year Price/Net Current Asset Value Range Min: 1.6   Max: 20.2 Current: 12.1 1.6 20.2
Price/DCF (Projected)	1	HOLX's Price/DCF (Projected) is ranked higher than 73% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.20 vs. HOLX: 1 )	HOLX' s 10-Year Price/DCF (Projected) Range Min: 0.8   Max: 5.7 Current: 1 0.8 5.7
Price/Median PS Value	1	HOLX's Price/Median PS Value is ranked higher than 71% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 0.90 vs. HOLX: 1 )	HOLX' s 10-Year Price/Median PS Value Range Min: 0.2   Max: 1.9 Current: 1 0.2 1.9
Earnings Yield (Greenblatt)	1.10	HOLX's Earnings Yield (Greenblatt) is ranked higher than 56% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 5.70 vs. HOLX: 1.10 )	HOLX' s 10-Year Earnings Yield (Greenblatt) Range Min: 0.6   Max: 7.9 Current: 1.1 0.6 7.9
Forward Rate of Return (Yacktman)	5.79	HOLX's Forward Rate of Return (Yacktman) is ranked higher than 66% of the 124 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 8.11 vs. HOLX: 5.79 )	HOLX' s 10-Year Forward Rate of Return (Yacktman) Range Min: -4.4   Max: 76.1 Current: 5.79 -4.4 76.1

Business Description

Hologic, Inc. was incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. The Company is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company's core business segments are focused on breast health, diagnostics, GYN surgical and skeletal health. The Company's breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce 3D images. The Company's diagnostic product offerings include the ThinPrep System used mainly for cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment. The Company's Third Wave acquisition enables it to develop and market molecular diagnostic reagents for a variety of DNA and RNA analysis applications based on Third Wave's proprietary Invader chemistry, including its two recently approved HPV tests. The Company's skeletal health products include a family of QDR dual energy x-ray bone densitometers and the Sahara Clinical Bone Sonometer, its mini C-arm imaging products and its Esaote line of extremity MRI systems, which are manufactured by an original equipment manufacturer. The Company's surgical product offerings include the NovaSure System, and the Adiana System. The NovaSure System enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner. The Adiana System is a form of permanent female contraception intended as an alternative to tubal ligation. It sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company's mammography and related products and subsystems compete on a worldwide basis with products offered by a number of competitors, including GE, Siemens, Philips, PlanMed, Agfa, Carestream Health, Fuji, IMS Giotto, Sectra and Toshiba. The manufacture, sale, lease and service of medical diagnostic and surgical devices and pharmaceutical products intended for commercial use are subject to extensive governmental regulation by the FDA in the United States and by a variety of regulatory agencies in other countries.
Company Website
SEC Reports

Industry:	Medical Instruments & Supplies
Compare:	WST, BAX, COV, TMO, COO
Traded in other countries:	HO1.Germany

» More Articles for HOLX

Headlines

Articles On GuruFocus.com

Weekly CFO Sells Highlight: KKR, DENN, NEE, HOLX, STT, INVN Aug 27 2012

Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX Aug 13 2012

The Portfolio of Mr. Zeke Ashton Analyzed - Buffett Ratio Guru Portfolio Analysis Jan 14 2012

Hologic Inc. (HOLX) Chairman John W Cumming sells 82,549 Shares Mar 09 2011

Hologic Inc. (HOLX) Chairman John W Cumming sells 50,000 Shares Mar 03 2011

Hologic Inc. Reports Operating Results (10-Q) Feb 03 2011

Meridian Funds Buys AME, JLL, USTR, PLL, ABFS, Sells HOLX, DLR, FNF, IGT Feb 01 2011

Prem Watsa of Fairfax Financial Q3: Buys RIMM, HOLX, Sells WFC, USB, KFT Nov 13 2010

Hologic Inc. Reports Operating Results (10-Q) Aug 05 2010

Iving Kahn Keeps His Top Holdings: New York Community Bancorp, Merck & Co., BristolMyers Squibb Comp May 07 2010

Personalized Checklist